Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Medical Officer Sayad Pierre Sargis acquired 168 Common Shares through a grant classified as a “grant, award, or other acquisition.” The shares were released from restriction on equity originally awarded on 3/28/2025 and carried no purchase price.

Following this compensation-related acquisition, Sargis directly holds 21,015 Common Shares. The event reflects routine equity compensation rather than an open‑market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sayad Pierre Sargis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	168	$0.00	--

Holdings After Transaction: Common Shares — 21,015 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 168 Common Shares Transaction price: $0.0000 per share Total holdings after: 21,015 Common Shares +1 more

4 metrics

Shares acquired 168 Common Shares Grant, award, or other acquisition on May 31, 2026

Transaction price $0.0000 per share No cash consideration for awarded shares

Total holdings after 21,015 Common Shares Direct ownership following the Form 4 transaction

Original award date March 28, 2025 Shares released from restriction from this prior award

Key Terms

Common Shares, Grant, award, or other acquisition, Chief Medical Officer, shares released from restriction

4 terms

Common Shares financial

"security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Chief Medical Officer financial

"officer_title: "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sayad Pierre Sargis

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	05/31/2026		A		168	A	$0	21,015	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Pierre Sayad	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Sayad Pierre Sargis?

Fennec Pharmaceuticals reported that Chief Medical Officer Sayad Pierre Sargis acquired 168 Common Shares. The acquisition was a grant classified as a “grant, award, or other acquisition,” reflecting equity compensation rather than an open‑market trade and increasing his direct holdings.

How many Fennec Pharmaceuticals (FENC) shares does Sayad Pierre Sargis hold after this Form 4?

After this transaction, Sayad Pierre Sargis directly holds 21,015 Common Shares of Fennec Pharmaceuticals. This total includes 168 shares that were newly acquired through release of restrictions on previously awarded stock granted on March 28, 2025.

Was cash paid for the 168 Fennec Pharmaceuticals (FENC) shares acquired by Sayad Pierre Sargis?

No cash was paid for these 168 shares; the transaction price per share was reported as 0.0000. The shares were released from restriction as part of equity compensation originally awarded on March 28, 2025, rather than purchased in the market.

What is the nature of the 168-share award to Fennec Pharmaceuticals (FENC) CMO Sayad Pierre Sargis?

The 168-share transaction is described as a grant, award, or other acquisition of Common Shares. A footnote explains the shares represent stock released from restriction that was originally awarded on March 28, 2025, indicating a vesting-type equity compensation event.

Does the Form 4 for Fennec Pharmaceuticals (FENC) show any insider sales by Sayad Pierre Sargis?

The Form 4 shows no sales by Sayad Pierre Sargis. It reports only one acquisition transaction coded “A” for 168 Common Shares, classified as a grant or award, with his total direct holdings increasing to 21,015 shares following this event.